Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756476 | 1.00 | KLK7 (0.34) | KLK7KLK5PLA2G10PLA2G5TPSAB1 | |
| SCHEMBL5756481 | 1.00 | KLK7 (0.34) | KLK7KLK5PLA2G10PLA2G5TPSAB1 | |
| SCHEMBL5756692 | 0.86 | TPSAB1 (0.32) | KLK7KLK5TPSAB1TPSD1TPSG1 | |
| SCHEMBL6860383 | 0.85 | LMNA (0.33) | — | |
| SCHEMBL5756646 | 0.85 | LMNA (0.33) | — | |
| SCHEMBL5756648 | 0.85 | LMNA (0.33) | — | |
| SCHEMBL4189082 | 0.84 | KLK7 (0.31) | KLK7KLK5PLA2G10PLA2G5 | |
| SCHEMBL5756270 | 0.84 | — | — | |
| SCHEMBL4189084 | 0.84 | KLK7 (0.31) | KLK7KLK5PLA2G10PLA2G5 | |
| SCHEMBL4189088 | 0.84 | KLK7 (0.31) | KLK7KLK5PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146043-B1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | UNIV FLORIDA STATE (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-6916942-B2 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| EP-1251846-B1 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6750246-B1 | NOVEL ORALLY ACTIVE PACLITAXEL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-15 | — | — | US | disclosed |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | FLORIDA STATE UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| EP-0667772-B1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV FLORIDA STATE (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| EP-1251846-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY | 2002-10-10 | — | — | US | disclosed |
| US-6335362-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR LEUKEMIA | FLORIDA STATE UNIVERSITY | 2002-01-01 | — | — | US | disclosed |
| EP-1146043-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001056565-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5739362-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0667772-A4 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | UNIV FLORIDA STATE (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0667772-A1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FLORIDA STATE UNIVERSITY (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010997-A1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FLORIDA STATE UNIVERSITY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250844-A1 | Methods of treating cancer using C-4 carbonate taxanes | CA4, CA14, CA13 | KLK7 1007/4885KLK5 1016/4885PLA2G10 3350/4885 |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | KLK7 4239/4885KLK5 4650/4885PLA2G10 2822/4885 |
| US-20040225009-A1 | Process for the preparation of C-4 carbonate taxanes | CA4, CA14, CDK4 | KLK7 1921/4885KLK5 2071/4885PLA2G10 4134/4885 |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | MCL1, TP53, EWSR1 | KLK7 4778/4885KLK5 4642/4885PLA2G10 3499/4885 |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | TOP2A, TOP2B, TUBB3 | KLK7 2160/4885KLK5 1730/4885PLA2G10 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.